Normal sun-exposed skin contains numerous epidermal patches that stain positive for p53 protein (p53 immunopositive patches; PIPs), which are considered potential early precursors of skin cancer. Whilst the TP53 gene is mutated in many PIPs, it is unclear whether PIPs contain any other cancer-related mutations. Here we report that PIPs, predominantly <3,000 p53 immunopositive cells in size, within normal chronically exposed skin contain mutations in multiple genes which are mutated in cutaneous squamous cell cancers. These mutations in the PIPs were not detected within the non-PIP epidermis of corresponding normal chronically exposed skin. Although some of these genetic alterations are clonal in the PIPs, many of the mutations are subclonal within these lesions. Similar mutations are seen in later precancers (actinic keratoses and Bowen's disease). Our results demonstrate that PIPs in chronically exposed skin contain multiple mutations in cancer-related genes. In addition, the results indicate that the clonal evolution of mutations which are seen within later precancerous lesions and in established malignancy can also occur in PIPs within normal human skin.
INTRODUCTION
Skin cancer is the most common cancer globally, with >5.4 million keratinocyte skin cancers, comprising cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), diagnosed annually in the USA (Rogers et al., 2015) . cSCC develops during a process of field cancerization, whereby exposure to ultraviolet radiation (UV) causes DNA damage, resulting in somatic mutations within epidermal keratinocytes, thus generating the initial genetic hit(s) for cancer development (Freeman et al., 1989; Ling et al., 2001 ).
Skin chronically exposed to sunlight contains numerous patches of epidermal cells which stain immunopositive for p53 protein (p53 immunopositive patches (PIPs), also known as "p53 mutant patches" and "p53 mutant clones"), with TP53 mutations reported in 29-64% of PIPs (Jonason et al., 1998; Kramata et al., 2005; Robinson et al., 2010) . As similar TP53 mutations have been described in PIPs and cSCCs in humans and murine models, it is thought that PIPs may represent early precursors of cSCC (Kramata et al., 2005; Rebel et al., 2005; Robinson et al., 2010) , although it is recognised that only a small proportion of PIPs may progress to skin cancer (Rebel et al., 2005) .
During later stages of skin carcinogenesis, cSCCs may arise from actinic keratoses (AKs) and/or Bowen's disease (BD) (Criscione et al., 2009; Kao, 1986; Mark et al., 1988) . Next generation sequencing has identified a number of key driver genes for cSCC development (Pickering et al., 2014; South et al., 2014) and recent work has demonstrated that sunexposed human skin contains numerous somatic mutations, some of which are within driver genes including NOTCH1, NOTCH2, TP53 and CDKN2A (Chitsazzadeh et al., 2016; Martincorena et al., 2015) . However, despite a potential role for PIPs in skin cancer development, it is unknown whether PIPs contain mutations in any other cancer-related genes apart from those reported in TP53. Here, we report that mutations in several cSCC driver genes are present in PIPs within normal chronically exposed skin but are not detected within the non-PIP epidermis of the same skin samples. Furthermore, many of these mutations, including those in the TP53 gene, are subclonal within the PIPs.
RESULTS

Identification of suitable gene targets for next generation sequencing in PIPs
Gene targets for next generation sequencing in PIPs were identified from cancer-related genes that were mutated in AKs and cSCCs. Initially, whole exome sequencing (WES) was conducted on dysplastic epidermis microdissected (using laser capture) from AKs (n = 5 AKs; supplementary figure 1); the mean sequencing depth across targeted bases was 86x (i.e. (Chitsazzadeh et al., 2016; Durinck et al., 2011; Lee et al., 2014; Li et al., 2015; Pickering et al., 2014; Ping et al., 2001; South et al., 2014) and the COSMIC database highlighted 18 known cancer-related genes mutated in AKs and cSCCs (figure 1a and supplementary data 2) which seemed suitable gene targets for next generation sequencing in PIPs.
PIPs contain mutations in multiple cancer-related genes
Identification of PIPs (figure 1b) was conducted using wholemount immunostaining for p53 protein in formalin-fixed epidermis from chronically sun-exposed normal skin (n = 40 subjects with PIPs). PIPs >2,500 cells (n = 23) were chosen for subsequent genetic analysis because this provided a minimum of 100ng total DNA per sample, thus there was no requirement for whole genome amplification (which might introduce artefacts during the amplification process). Following microdissection of these PIPs and corresponding non-PIP epidermis from the same subjects, target-enriched sequencing of the 18 genes was performed.
Sequencing data was obtained on 21 PIPs, with a median breath of coverage at 100X of 75.8% across targeted bases in 15 of these PIPs. Patch size of these 15 PIPs ranged from 2,592-4,751 p53 immunopositive cells, equating to 0.14-0.27 mm 2 of epidermis, with most <3,000 p53 immunopositive cells (figure 1b). The mutation burden in the 18 selected genes in the PIPs was 0.03 mutations per Kb (equivalent to 30 mutations per Mb). Non-silent somatic mutations were identified in all 15 PIPs, but these mutations were not detected in the surrounding p53 negative epidermis. TP53 mutations were seen in 60% (9/15) of PIPs (figure 1c), consistent with the proportion of PIPs containing TP53 mutations in the literature (Jonason et al., 1996; Kramata et al., 2005; Robinson et al., 2010) . Interestingly, 13 of the 18 genes were mutated within PIPs, with at least 3 genes mutated in 60% (9/15), at least 5 genes mutated in 27% (4/15), and mutations of GPR98, TP53, NOTCH1 and MLL2 seen in 6 or more PIPs (figure 1c and supplementary data 1). Occasional allelic losses (inferred from sequencing data) were also seen in the PIPs (6/15) at some of these loci (Table 1) .
Cancer-related gene mutations in AKs and BDs
Amplicon-based next generation sequencing of the same genes was conducted, following laser capture microdissection, on dysplastic and/or neoplastic keratinocytes from 32 additional samples that were AKs (including 7 AKs where a cSCC was adjoining the AK in the same histological section and considered to have arisen from the adjacent AK) and 37
BDs (including 8 BDs where the cSCC adjoined the BD and thought to have developed from the BD) as well as on corresponding non-lesional skin. 24 AKs (including 6 AK/cSCCs) and 23 BDs (including 6 BD/cSCCs) gave a median breath of coverage at 100X of 57% and 62.3% across targeted bases in these lesions respectively. Non-silent somatic mutations in 16 of these 18 genes were observed in the AKs and/or BDs, as well as in most cSCCs ( figure 2a-d 
Comparison of mutations in PIPs and later precancerous/cancerous lesions
The non-silent:synonymous mutation ratio for the 18 genes was 2.6 in PIPs, which was below that in AKs (3.4) and BDs (3.1) but higher than that in the cSCCs (2.2). All 13 genes with non-silent mutations in PIPs were mutated in the AKs, BDs and cSCCs in this study ( figure   3a ). Certain mutations were identical (i.e. same amino acid alteration in same gene) in different lesions ( figure 3b-d figure   4a ). Some AKs and one BD contained clonal TP53 mutations, whereas mutation of this gene was subclonal in others, and the VAF was significantly higher for TP53 mutations than for other mutations in the AKs and BDs (p < 0.001 in each lesion; figure 4a). In PIPs lacking TP53 mutation, the VAF for NOTCH1 mutations was significantly higher than that for other mutations (p < 0.01), whereas this difference in VAF between NOTCH1 mutations and other mutations was less obvious for AKs and BDs (figure 4a).
Tracking shared mutations in PIPs and in later precancerous/cancerous lesions
Most PIPs were single lesions taken from different subjects, but in two cases more than one discrete PIP was isolated from different areas of the epidermis from an individual skin sample.
In one of these cases, 4 PIPs were isolated (figure 5a) and the sequencing data showed shared mutations (including silent and non-synonymous mutations, with up to 10 shared mutations across PIPs), with additional distinct mutational differences between each of these PIPs, suggesting that all 4 PIPs had originated from a shared precursor cell pool and had evolved along a common mutation pathway before diverging into separate clones of cells (figure 5b).
Moreover, in one of these clones, despite two existing shared NOTCH1 mutations, an additional NOTCH1 missense mutation was observed, suggesting selection of NOTCH1 mutations. In the other case with 2 PIPs, the mutations within each PIP were distinct, suggesting that both PIPs had arisen independently (figure 5c). Shared mutations were also seen in the AK/cSCC and BD/cSCC groups. In some of these cases, there were multiple shared mutations in the AK and corresponding cSCC and/or in the BD and associated cSCC, suggesting that the cSCC had arisen from the AK and/or BD (figure 5d,e). In other cases, there were common shared mutations, but additional unique mutations in both the cSCC and the AK and/or BD, suggesting that both the cancer and precancerous lesions at the time of sampling had evolved since developing from a common precursor lesion (figure 5f and supplementary figure 4). In one of the latter cases (figure 5f), mutations in CDKN2A, TP53
and NOTCH1 occurred after this common precursor stage, and may have provided the oncogenic drive for development of the cSCC.
DISCUSSION
The results of this study reveal that PIPs in normal sun-exposed skin contain mutations in multiple cancer-related genes and that, whilst some of these mutations are clonal, many mutations within PIPs are subclonal. The TP53 gene was mutated in 60% of these PIPs, which is consistent with previous reports (Jonason et al., 1998; Kramata et al., 2005; Robinson et al., 2010; Rebel et al., 2005) . In those studies, Sanger sequencing of TP53 was performed, and other genes were not sequenced, so it was possible that TP53 gene mutations in some PIPs might have been missed due to contamination by normal keratinocytes. The use of next generation sequencing of 18 genes and the identification of other genes mutated in
PIPs lacking TP53 mutations in this current study demonstrates convincingly that the TP53 coding sequence is not mutated in a substantial number of PIPs. In addition, based on the observation of subclonal TP53 mutations in PIPs with mutated TP53, including those PIPs with clonal mutations in other genes, it is possible that the TP53 mutation occurred (at least in some cases) after the initial genetic hit which initiated development of the PIP.
As none of the mutations in the PIPs were detected in the surrounding epidermis, the mutation burden of 0.03 mutations per Kb (i.e. 30 mutations per Mb) in the PIPs was likely to be greater than the surrounding skin in general. Indeed, when reciprocal variant calling was performed using the PIP as the 'normal' (germline) sample, there were fewer variants called (median of 2 versus 9, p = 0.02; 2-sided Mann-Whitney) consistent with the mutation burden being higher in the PIPs. However, based on work by Martincorena et al. (2015) in which they used the pigeonhole principle following next generation sequencing to identify mutations co-occurring in the same subclone in random samples of chronically exposed skin, we suspect that the p53 negative epidermis may have contained additional "p53 invisible"
clones, i.e. clones of cells which would not have been apparent with p53 immunostaining used to identify the PIPs for subsequent genetic analysis.
We did identify clonal non-synonymous mutations of CDKN2A, MLL2, GPR98 and CACNA1C in some PIPs and clonal synonymous mutations of TEX15, HMCN1, FAT1, PTCH1 and EP300 in other PIPs. This confirms the view in the published literature that PIPs are clones of p53 immunopositive cells, having been called "clones of p53-mutated keratinocytes" (Jonason et al., 1996) , "p53 mutant clones" (Zhang et al., 2005) , "epidermal p53 clones" (Bäckvall et al., 2004a (Bäckvall et al., , 2004b , "p53 immunopositive clones" (Tabata et al., 1999) and "p53-mutant early clones" (Voskamp et al., 2013) by other authors. However, a number of the mutations in the PIPs were subclonal in the current study and the 4 interrelated PIPs in one individual which had arisen from a single precursor cell pool and evolved along a common pathway before diverging into separate clones provides additional insight into the heterogeneity in PIP evolution. Interestingly, based on recent findings of subclonal alterations in individual glands within colorectal tumours, it has been proposed that both clonal and subclonal alterations arise early during cancer growth; the latter has been termed the "big bang model" of cancer development (Sottoriva et al., 2015) . Some authors consider
PIPs as potential early precursors of non-melanoma skin cancer (Kramata et al., 2005; Rebel et al., 2005) , however, only a small proportion of PIPs are likely to progress to skin cancer.
While we cannot know whether the PIPs we sequenced would have developed into skin cancer if they had been left in situ in the skin, our data does provide support for a "big bang model" where clonal and subclonal alterations occur in clinically invisible lesions, which in our study were generally <3,000 p53 immunopositive cells in size.
The finding of multiple identical genes mutated in PIPs, AKs, BDs and cSCCs, and that shared mutations were present in PIPs and AKs, PIPs and BD, and PIPs and cSCCs would be consistent with the possibility that PIPs could evolve into these other lesions. However, the VAF for TP53 mutations was not significantly different to the VAF for other mutations in the PIPs, which is in contrast to the case in the AKs and BDs where TP53 mutations appeared to have arisen earlier than many of the other detected genetic events in the same set of genes.
The fact that it is not possible to identify PIPs and monitor them in vivo in human skin at the present time to see whether any of them develop into AKs, BDs or cSCCs means that it is unclear whether cSCCs develop from PIPs and/or from other early clinically invisible clonal lesions in skin. The observation that many similar genes were mutated in AKs and cSCCs as well as in BDs and cSCCs in the current study supports the view from previous clinical observations that human cSCCs can arise from AKs and BDs (Arlette and Trotter, 2004; Criscione et al., 2009; Kao, 1986; Marks et al., 1988; Quaedvlieg et al., 2006) . Moreover, our data on shared mutations in the AK/cSCC and BD/cSCC adjoining lesions reinforces this view, while also demonstrating subclonal evolution at these later precancerous (AK and BD) and cancerous stages of cSCC development.
The WES results of AKs in this study demonstrates that AKs contain a greater mutation burden than reported for many highly fatal malignancies, including in pancreas, lung, ovary, as well as cutaneous melanoma (Kandoth et al., 2013; Vogelstein et al., 2013) . The mutation burden of 34.5 per Mb in this study was also higher than 18.5 per Mb reported recently for a group of 7 AKs, but may reflect that we isolated the dysplastic keratinocytes using laser capture microdissection, thus reducing contamination by normal keratinocytes and cells within the immune infiltrate (Chitsazzadeh et al., 2016; Lai et al., 2016) . Indeed, the mutation burden within our AKs was similar to that reported in cSCCs, suggesting that minimal additional genetic events may be necessary for some AKs to progress to cSCCs.
Similar to the targeted sequencing, WES analysis also demonstrated allelic loss in our AKs, including one AK with extensive loss of heterozygosity (supplementary table 1), consistent with the previous report of high frequency of allelic losses in AKs (Rehman et al., 1994) .
However, despite the high mutation load in AKs, previous observational studies have reported that 26% to 74% of AKs in humans can regress either spontaneously or with the use of sunscreen (Frost et al., 2000; Marks et al., 1986; Thompson et al., 1993) .
The results of this study establish that mutations in multiple cancer-related genes are present in PIPs, many of which are < 3,000 p53 immunopositive cells in size, within chronically sunexposed human epidermis. Furthermore, these PIPs show evidence of clonal and subclonal genetic alterations, signifying that subclones of cells containing additional cancer-related mutations develop within these clinically invisible lesions as they evolve within normal sunexposed skin.
MATERIALS AND METHODS
Samples
Archived formalin-fixed paraffin-embedded (FFPE) AK, BD, AK/cSCC and BD/cSCC samples were obtained from University Hospital Southampton NHS Foundation Trust.
Chronically sun-exposed skin (which looked normal and without any visible skin lesions) was obtained from the face and dorsum of the hands during surgical procedures for removal of skin lesions, where redundant normal skin was subsequently resected to allow apposition of wound edges for optimal wound closure. The study was conducted under ethical approval provided by the South Central Hampshire B NRES Committee (reference number 103 07/H0504/187). Informed consent was provided by all study subjects.
DNA extraction
Following sequential cutting of 10μm FFPE tissue sections, dysplastic/neoplastic keratinocytes and, separately, normal skin were isolated using LCM of cresyl violet acetate stained sections. Epidermal PIPs were identified by immunostaining of wholemount epidermis as previously described (Jonason et al., 1996) with an anti-p53 antibody (DO-7, Novocastra). Genomic DNA was purified using QIAamp DNA FFPE Tissue Kit (Qiagen).
DNA quantity and quality was assessed by Nanodrop D-1000 (Nanodrop Technologies, US) absorbance spectrophotometer, Qubit 2.0 fluorometer (Invitrogen) and multiplex PCR to amplify 100-600bp fragments (Van Dongen et al., 2003) .
DNA sequencing
WES and target-enriched resequencing were conducted in the Wellcome Trust Centre for Human Genetics, Oxford, UK. WES used the SureSelect V5 (Agilent V5) exome capture kit for library preparation and the Illumina HiSeq2000 system for sequencing whereas targetenriched resequencing utilised the TruSeq custom amplicon kit v1.5 (Illumina) for target capture and Illumina MiSeq system for sequencing. Detailed methods for read mapping and variant calling and for determination of clonal and subclonal mutations are provided in the supplementary data (supplementary materials and methods).
Selection of genes for target-enriched resequencing
WES data from AKs was filtered, and only those genes with potentially deleterious (according to SIFT and PolyPhen algorithms) somatic mutations were considered as a potential target for target-enriched resequencing. These genes were then assessed against genes reported previously in sequencing data, including WES data, from cSCC (Durinck et al., 2011; Lee et al., 2014; Li et al., 2015; Pickering et al., 2014; Ping et al., 2001; South et al., 2014; Ziegler et al., 1994) and in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (accessed 30/03/2015). Eighteen genes which were mutated in AKs and cSCCs and catalogued in COSMIC were then chosen for target-enriched resequencing (see supplementary data 2 for the relevant genes). Based on a background mutation rate of 6 per Mb, it was estimated that a cohort size of 23 would have 80% power to detect a gene as significantly mutated in 40% of patients (http://www.tumorportal.org/advanced_power).
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command to remove clusters of false positives and SNV calls near indels with the same frequency and depth thresholds. were retained for analysis. Regions of loss of heterozygosity (LOH) were assessed using BAFsegmentation (Staaf et al., 2008) considering only variants which had a read depth of greater than 50X in both samples to improve the accuracy of allelic ratio determination.
Targeted resequencing paired-end raw FastQ reads were trimmed of adapter sequence using Skewer (Jiang et al., 2014) and paired end overlaps merged using FLASH (Magoc and Salzberg, 2011) . Processed reads were then aligned to reference genome GRCh37 (hg19) using BWA (Li and Durbin, 2009 
